Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic therapy in acute ischemic stroke - basic concepts.

Atte Meretoja1, Turgut Tatlisumak

  • 1Department of Neurology, Helsinki University Central Hospital, Finland. atte.meretoja@hus.fi

Current Vascular Pharmacology
|February 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute non-alcoholic caffeinated beverage consumption as a trigger for cryptogenic ischemic stroke in the young: findings from the SECRETO study.

Journal of neurology·2026
Same author

Effect of tranexamic acid for acute spontaneous intracerebral haemorrhage: a systematic review and individual patient data meta-analysis.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Association Between Physical Activity and Cryptogenic Ischemic Stroke in Young Adults: A Case-Control Study.

European journal of neurology·2026
Same author

Antipsychotics and Their Association With Long-Term Outcomes in Young Ischemic Stroke Patients.

European journal of neurology·2026
Same author

Associations between retinal microvasculature and cognition in middle-aged adults with type 1 diabetes without overt neurological symptoms.

Cerebral circulation - cognition and behavior·2026
Same author

Perihematomal Edema and Functional Outcome After Intracerebral Hemorrhage: A Meta-Analysis of Individual Participant Data.

Stroke·2026
Same journal

Chronic Treatment with Renin-Angiotensin System Inhibitors at Hospital Admission is Associated with Improved Reperfusion and Mortality Among STEMI Patients Undergoing Mechanical Reperfusion: Insight from the ISACS-STEMI COVID-19 Registry.

Current vascular pharmacology·2026
Same journal

Steps to Walk Out of, or Side Track, Cardiovascular Disease to Achieve Longevity.

Current vascular pharmacology·2026
Same journal

Mast Cells and Cardiovascular Disorders.

Current vascular pharmacology·2026
Same journal

Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature.

Current vascular pharmacology·2026
Same journal

Metalloproteinases 2 and 9 as Biomarkers in Acute Elevation of Blood Pressure.

Current vascular pharmacology·2026
Same journal

Is the Cardiovascular Risk Increased in Patients with Isolated Systolic Hypertension and Anemia?

Current vascular pharmacology·2026
See all related articles

Alteplase is a standard thrombolytic therapy for acute ischemic stroke within 3 hours. New trials are exploring extended time windows and alternative drugs like tenecteplase for improved patient outcomes.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Thrombolytic therapy, primarily with alteplase, is a critical treatment for acute ischemic stroke, but its efficacy is time-limited to within 3 hours of symptom onset.
  • Current clinical practice involves careful patient selection for alteplase administration.
  • Ongoing research aims to expand the therapeutic time window for stroke treatment.

Purpose of the Study:

  • To review the current status and future directions of thrombolytic therapies in acute ischemic stroke.
  • To explore the potential of extended time windows and novel thrombolytic agents.
  • To highlight the importance of understanding coagulation and fibrinolytic systems for optimizing stroke treatment.

Main Methods:

  • Review of existing clinical trials and research on thrombolytic agents for acute ischemic stroke.

Related Experiment Videos

  • Analysis of the roles of coagulation and fibrinolytic systems in stroke pathophysiology.
  • Discussion of potential new drug development and adjuvant therapies.

    • Main Results:

    • Alteplase is established for acute ischemic stroke within 3 hours.
    • Trials are investigating extended time windows with alteplase and desmoteplase.
    • Tenecteplase, reteplase, and staphylokinase are under evaluation for stroke treatment.

    Conclusions:

    • A deeper understanding of coagulation and fibrinolysis can guide drug development and improve patient management.
    • Expanding treatment windows and evaluating new agents like tenecteplase hold promise for more stroke patients.
    • Future adjuvant therapies may benefit non-responders to standard thrombolysis and enhance overall treatment efficacy.